Compass Therapeutics (NASDAQ:CMPX) Issues Earnings Results

Compass Therapeutics (NASDAQ:CMPX) announced its earnings results on Tuesday. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10), FiscalAI reports.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX traded down $0.05 during midday trading on Wednesday, reaching $1.91. The stock had a trading volume of 2,292,950 shares, compared to its average volume of 5,324,203. The stock has a 50-day moving average of $5.10 and a 200-day moving average of $5.21. The company has a market capitalization of $343.07 million, a price-to-earnings ratio of -4.43 and a beta of 0.79. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88.

Wall Street Analyst Weigh In

CMPX has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Monday, April 20th. Guggenheim restated a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a research report on Tuesday, March 24th. Jefferies Financial Group restated a “buy” rating and issued a $9.00 price target on shares of Compass Therapeutics in a research report on Thursday, March 5th. D. Boral Capital restated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research report on Monday, April 27th. Finally, Craig Hallum started coverage on Compass Therapeutics in a research report on Friday, February 13th. They issued a “buy” rating and a $15.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.60.

Institutional Trading of Compass Therapeutics

Several institutional investors have recently made changes to their positions in CMPX. Strs Ohio purchased a new stake in shares of Compass Therapeutics during the first quarter worth about $34,000. Creative Planning purchased a new position in Compass Therapeutics during the second quarter valued at $30,000. XTX Topco Ltd purchased a new position in Compass Therapeutics during the second quarter valued at $84,000. Invesco Ltd. grew its stake in Compass Therapeutics by 58.1% during the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after acquiring an additional 21,578 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after acquiring an additional 449,868 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.